The first two authors contributed equally.
p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium
Article first published online: 26 OCT 2010
Copyright © 2010 EMBO Molecular Medicine
EMBO Molecular Medicine
Volume 2, Issue 11, pages 472–486, November 2010
How to Cite
Cole, A. M., Ridgway, R. A., Derkits, S. E., Parry, L., Barker, N., Clevers, H., Clarke, A. R. and Sansom, O. J. (2010), p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. EMBO Mol Med, 2: 472–486. doi: 10.1002/emmm.201000101
- Issue published online: 4 NOV 2010
- Article first published online: 26 OCT 2010
- Manuscript Accepted: 29 SEP 2010
- Manuscript Revised: 28 SEP 2010
- Manuscript Received: 12 MAR 2010
- colorectal cancer;
- renal carcinoma;
Senescence has been implicated as an important mechanism of tumour suppression in a number of human malignancies, including colorectal cancer (CRC). However, we still have a relatively poor understanding of how the underlying mutations that occur in cancer cause senescence and its relevance in vivo. The Apc gene is mutated in approximately 80% of CRC as the initiating event, but rarely elsewhere. In this study we have examined the capacity of Apc loss to induce senescence in the intestinal epithelium compared to the renal epithelium. Within the renal epithelium, loss of Apc function led to an induction of senescence, however, bypassing senescence through combined Apc and p21 or Ink4A gene deletion rapidly initiated renal carcinoma. Within the intestinal epithelium, loss of Apc did not induce senescence. Moreover, combined Apc and p21 or Ink4A loss had no impact upon tumourigenesis. Taken together, these results show that Apc loss in vivo invokes a senescence program in a context-dependent fashion, and implies senescence may play a key barrier to tumourigenesis in the kidney. However, in CRC, escape from senescence is likely to only be a barrier in cancers initiated by other mutations.